on behalf of the Comparison of Safety and Primary Patency Between the FUSION BIOLINE Heparin-Coated Vascular Graft and EXXCEL Soft ePTFE (FINEST) Trial Co-investigators, Houston, Tex; and New York, NY Objective: Despite improvements in endovascular therapy for lower extremity arterial disease, open surgical revascularization is still required when the disease is extensive. Although autogenous vein is the conduit of choice for open femoropopliteal bypass, prosthetic grafts can be an acceptable alternative when adequate vein is not available. The FUSION BIOLINE heparin-coated vascular graft (Maquet Endovascular, Wayne, NJ) was developed to improve the patency rate associated with standard prosthetic grafts. The current study, the FINEST Trial (Comparison of Safety and Primary Patency Between the FUSION BIOLINE Heparin-Coated Vascular Graft and EXXCEL Soft ePTFE)
necessary when symptoms are severe. Femoropopliteal bypass is performed to salvage limbs that might otherwise require amputation in patients with ischemic rest pain or tissue loss and to improve symptoms in patients with lifestyle-limiting claudication. [3] [4] [5] [6] Endovascular interventions are increasing in frequency, but open infrainguinal bypass surgery for limb salvage still accounts for just under 50% of lower extremity arterial procedures. 7 Open procedures will continue to play an important role in the treatment of lower extremity arterial disease, noting inferior patency rates of endovascular procedures when the underlying lesion is long, heavily calcified, or associated with reduced outflow. 8, 9 Saphenous vein is the conduit of choice for revascularization, particularly when the outflow site is below the level of the knee. [10] [11] [12] Many patients, however, may not have a suitable vein available due to previous vein harvest or poor vein quality. 13 In such cases, surgeons rely on prosthetic grafts as alternative conduits. However, the patency rates with prosthetic grafts are generally inferior to those achieved with autogenous conduits.
Heparin-coated grafts were developed to decrease thrombogenicity and potentially improve the patency of prosthetic conduits. [14] [15] [16] Heparin coatings are associated with early antithrombotic effects at the blood-graft interface by inhibiting platelet aggregation and thrombin production at the time when a graft is most thrombogenic. 17 Two randomized clinical trials demonstrated improved patency of heparincoated bypass grafts compared with standard expanded polytetrafluoroethylene (ePTFE) grafts. 18, 19 Here we report the outcome of a novel heparin-coated vascular graft compared with standard ePTFE for femoropopliteal arterial bypass.
METHODS
The FINEST Trial (Comparison of Safety and Primary Patency Between the FUSION BIOLINE Heparin-Coated Vascular Graft and EXXCEL Soft ePTFE [standard ePTFE graft]) was conducted under an investigational device exemption (IDE) application provided to the U.S. Food and Drug Administration using a protocol submitted for a significant risk device investigation. Patients requiring prosthetic aboveknee or below-knee femoropopliteal bypass were screened for eligibility. Those who satisfied eligibility criteria and provided written informed consent were randomly assigned to the standard ePTFE graft or the FUSION BIOLINE heparin-coated graft (Maquet Cardiovascular, Wayne, NJ).
Medical history and risk factors were recorded before the procedure, including Rutherford clinical category, symptoms, conditions, and rest ankle-brachial index (ABI). Duplex ultrasound imaging and ABI evaluations were performed at 30 days, 6 months, and 12 months after the study graft implant procedure. Adverse event evaluation was performed at each follow-up visit. Any scheduled or unscheduled visits for endovascular, surgical, or other graft intervention were also recorded.
Study devices. The FUSION BIOLINE heparincoated vascular graft offers the key characteristics of polyester knitted grafts and ePTFE grafts. The inner layer consists of extruded ePTFE, and the outer layer is of knit polyester textile. The two layers are fused with polycarbonate-urethane adhesive. The luminal surface of the graft has a bioactive surface coating consisting of covalent heparin sodium coupled to recombinant human albumin. The graft is supplied in a supported version for enhanced kink and compression resistance that includes an external polypropylene core and continuous removable polyethylene sheath coil wrapped around the exterior of the polyethylene terephthalate layer.
The control standard ePTFE device was the EXXCEL Soft Graft (Maquet Cardiovascular), fabricated from extruded ePTFE, with or without an ePTFE monofilament external support coil. EXXCEL vascular grafts were cleared for market by the U.S. Food and Drug Administration in 1997 and have been in clinical use since that time.
Study design. This prospective multicenter, randomized, controlled trial was designed to compare the FUSION BIOLINE vascular graft and the standard ePTFE graft in w200 patients undergoing femoropopliteal bypass for chronic lower extremity peripheral arterial disease. The study was conducted at 25 investigational sites in the U.S. (18) and Europe (seven), which are listed in the Appendix, online only.
The study was sponsored by Maquet Cardiovascular and was registered on ClinicalTrials.gov before commencement (NCT01113892). The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Each investigative site was required to obtain Institutional Review Board/Ethics Committee approval before patient enrollment, and all study participants gave written informed consent.
At the time of randomization, the study site personnel received graft assignments from the electronic data capture system. Randomization was balanced to ensure that each site enrolled approximately equal numbers in each treatment group. After randomization assignment, the operating surgeon decided on the diameter and length of the graft and chose an externally supported or unsupported model on the basis of the patient's anatomy. The choice of suture, heparin and protamine regimens, and topical hemostatic agents was not protocol-specified but was left to the individual surgeon's standard of care. Postoperative aspirin therapy was required in all patients. Study data were recorded and entered into the electronic data capture system by trained site personnel. Patient data and study conduct were fully monitored by independent clinical research associates.
Primary safety-related and efficacy-related events, deaths, and unanticipated adverse device effects were adjudicated by an independent Clinical Events Committee (CEC), which reviewed original source documentation, including clinic notes, duplex ultrasound imaging, ABI, angiography, and operative reports. The CEC made a determination of device-relatedness or procedure-relatedness for all primary end points and target limb reinterventions. An independent Data Safety Monitoring Board met periodically and reviewed summary adverse event tables and listings to ensure patient safety and to make recommendations on study protocol modifications or termination of the trial.
Study population. Patients were eligible for inclusion in the study if they required an above-knee or below-knee femoropopliteal bypass with the proximal anastomosis at the level of the distal external iliac, common femoral, profunda femoral, or proximal superficial femoral artery. The study protocol specified that a prosthetic femoropopliteal bypass must be medically necessary, but did not, per se, exclude those without an adequate autogenous conduit. Patients with Rutherford category 1 to 5 ischemia were eligible, with symptoms of claudication, rest pain, or with superficial ulceration in the target lower extremity.
Candidates were ineligible if they presented with an acute arterial occlusion requiring urgent intervention, if they had undergone a prior open surgical bypass in the target extremity, or if angioplasty or stenting had been performed at the site of a planned anastomosis within the previous 30 days. Also excluded were patients with serum creatinine >2.5 mg/dL, recent (<6 weeks) myocardial infarction or stroke, coagulation or bleeding disorders, and those receiving warfarin therapy where oral anticoagulation could not be withheld.
Study end points and statistical considerations. The primary efficacy end point was primary graft patency at 6 month as assessed by duplex ultrasound imaging and ABI. The primary safety end point was the composite of major adverse limb events or periprocedural death (MAL-EþPOD), where MALE included major amputation, major graft reintervention with placement of a new graft or an interposition graft, open or percutaneous graft thrombectomy, pharmacologic thrombolysis, or graft excision. 20 PODs included those that occurred #30 days of the index procedure or any remedial procedure performed at the same anatomic site. Secondary efficacy end points included primary assisted patency, secondary patency, and bleeding at the suture hole as judged subjectively by the operating surgeon and objectively by recording the time between restoration of flow into the graft and the absence of detectable bleeding from the suture holes.
The primary efficacy evaluation was a noninferiority analysis of the primary efficacy end point of primary graft patency 6 months after graft implantation. The primary study hypothesis to be tested was whether the primary patency rate at 6 months for the FUSION BIOLINE graft was not inferior to that of the standard ePTFE graft, with a noninferiority margin set at 15%. The assumption at the time of the study design was that the ratio of above-knee to below-knee procedures would be 60:40. This distribution was used to estimate a 79% primary patency rate for the combined above-knee and below-knee bypasses within each treatment group. [21] [22] [23] [24] [25] Assuming a power of 80%, it was determined that 91 patients per treatment group were needed. Adjusting for a 10% withdrawal rate prior to the 6month evaluation, the study sample size was set at 200 patients: 100 within each treatment group. The sensitivity of the 200-patient sample size was evaluated for the primary safety end point of MALE or POD. If the rate of MALE and POD in participants who received the control graft was 15%, 20 a sample size of 100 individuals in each treatment arm would detect an increase from 15% to 30% with 80% power and at a one-sided significance level of 0.05. Secondary efficacy end points were analyzed in a sequential fashion after demonstrating noninferiority for the primary efficacy variable. Categoric variables were analyzed with the c 2 or Fisher exact test, where appropriate. No adjustment for multiple testing was required by virtue of the sequential testing of 6-month primary assisted patency, 6-month secondary patency (c 2 tests), and time to hemostasis (unpaired t-test).
RESULTS
Between May 2010 and June 2012, the trial enrolled 209 study patients at 18 U.S. and seven European investigational sites: 101 in the standard ePTFE control group and 108 in the FUSION BIOLINE group. Among these, two individuals in the FUSION BIOLINE group did not undergo graft implantation and a nontest graft was implanted in one, leaving 206 participants (101 standard ePTFE and 105 FUSION BIOLINE patients) in the safety analysis population. Of the 207 treated patients, data were not available for the 6-month primary end point in one standard ePTFE patient and in three FUSION BIOLINE patients, leaving 203 patients (100 standard ePTFE and 103 FUSION BIOLINE) in the efficacy analysis population.
Baseline characteristics. The demographics and baseline characteristics are reported in Table I and were comparable for the two treatment groups. The study participants were a mean age of 64.7 years (range, 40-87 years); however, 58.3% of study patients in the FUSION BIOLINE group were aged $65 years vs 41.0% in the standard ePTFE group (P ¼ .0017). Claudication was the presenting symptom in 147 study participants (72.4%), 34 (16.8%) had ischemic rest pain, and 22 (10.8%) presented with ulceration or localized gangrene. The mean baseline ABI was 0.55 (standard deviation [SD], 0.22). The most common comorbidities included hypertension (85.7%) and hyperlipidemia (70.4%), and 51.7% were current tobacco users (Table II) . Baseline medications included aspirin (84.7%), an angiotensin-converting enzyme inhibitor (84.7%), and a statin (63.5%). Small numbers of participants were receiving clopidogrel (13.8%), another antiplatelet agent (5.9%), or warfarin (3.4%). Graft implantation procedures. Most patients underwent above-knee bypass: 86 (86.0%) in the FUSION BIOLINE group and 88 (85.4%) in the standard ePTFE group (Table III) . The procedure in both groups lasted w2 hours. Local hemostatic agents were used more often with the standard ePTFE grafts (64.0% vs 30.1%; P < .0001 by c 2 test). The mean time to hemostasis was significantly shorter in the FUSION BIOLINE group at 3.5 (SD, 4.7) minutes vs 11.0 (SD, 10.6) minutes (P < .0001).
Graft patency. The primary end point of 6-month primary graft patency was achieved in 89 of 103 patients (86.4%) in the FUSION BIOLINE treatment group and in 70 of 100 (70.0%) in the standard ePTFE control group (P ¼ .006). With eight patients lost to follow-up, the corresponding primary patency rates at 12 months were 67 of 97 (67.0%) in the FUSION BIOLINE and 75 of 98 (76.5%) in the standard ePTFE group. The study met its primary efficacy analysis of noninferiority of the FUSION BIOLINE graft (P < .0001). A secondary analysis of superiority at 6 months was confirmed by the Fisher exact test (P ¼ .006).
The Fig shows the Kaplan-Meier curve with an estimated 6-month primary patency rate of 87.3% (95% confidence interval [CI], 78.3%-95.2%] for the FUSION BIOLINE group compared with 74.0% [95% CI, 61.8%-85.0%] in the standard ePTFE group (P ¼ .013). The primary patency benefit persisted through 1 year, with 12-month Kaplan-Meier primary patency estimates of 75.3% (95% CI, 62.3%-88.2%) and 65.8% (95% CI, 51.3%-80.3%) in the FUSION BIOLINE and standard ePTFE treatment arms, respectively (P ¼ .05). Primary-assisted and secondary patency rates were higher in the FUSION BIOLINE group at 30 days, 6 months, and 12 months, but without statistically significant differences between the two treatment groups except for statistically superior 6-month primary and primary assisted patency in the FUSION BIOLINE group (Table IV) .
No influence was found for site (U.S. vs non-U.S., P ¼ .855), gender (P ¼ .341), or age group (<65 vs $65 years, P ¼ .545) on 12-month primary graft patency. Although the proportion of below-knee femoropopliteal bypasses was small, the 6-month and 12-month primary patency rates did not differ by the site of outflow (Table V) . In patients presenting with claudication, the primary patency in the FUSION BIOLINE group was significantly higher at 6 months (P ¼ .003) and 12 months (P ¼ .012 l; Table VI ). Patency did not differ significantly in participants with rest pain or tissue loss. Table VII ). Major amputations were necessary in seven participants: five in the FUSION BIOLINE group (4.8%) and two in the standard ePTFE group (2.0%). Each of the major amputations occurred after graft thrombosis, although infection of a nonstudy graft preceded amputation in one of the eight patients. One procedure-related death occurred in each treatment group, as adjudicated by the CEC. Four additional deaths were reported: three in the FUSION BIOLINE group and one in the standard ePTFE group. None of the deaths were device-related. All were related to cardiac causes and occurred between 73 and 339 days after the graft implant procedure.
Major graft reinterventions occurred in 17 FUSION BIOLINE patients (16.2%) vs 31 patients (30.7%) treated with standard ePTFE (P ¼ .033). No unanticipated devicerelated events occurred in either treatment group. Devicerelated adverse events occurred in 28 of 105 (26.7%) and in 41 of 101 (40.6%) of the FUSION BIOLINE and standard ePTFE groups, respectively (Table VIII) .
Bypass graft infections occurred in three patients in the FUSION BIOLINE group (2.9%) and were reported on postoperative days 36, 88, and 140. The infection involved 
DISCUSSION
Before the mid-20th century, few treatment options were available for symptomatic lower extremity arterial disease. The advent of arteriography by Dos Santos 26 in 1929 paved the way for lower extremity arterial revascularization, first with saphenous vein bypass in the late 1940s by Leriche and Kunlin, 27 with prosthetic grafts by Voorhees et al 28 a few years later, and with the development of ePTFE conduits in the 1970s. 29 Despite improvements in the quality of prosthetic grafts, patency rates remained inferior to autogenous vein grafts, particularly when the site of the distal anastomosis was below the level of the knee joint. 
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Heparin coatings on the inner surface of prosthetic grafts were first evaluated in animals in the 1980s and later in clinical studies in the 1990s. Significant improvements in patency were observed with heparin-coated polyester and with heparin-coated ePTFE grafts compared with uncoated ePTFE grafts for femoropopliteal reconstruction. 14, 18, 19, 30, 31 The ePTFE grafts, however, continue to be plagued by suture-hole bleeding, which can be considerable in occasional cases. 32 The findings of the FINEST Trial document improved patency rates compared with standard ePTFE grafts used in the femoropopliteal position. Although the study was designed as a noninferiority trial to support a claim of substantial equivalence for regulatory clearance purposes, superiority was demonstrated at 6 months and marginally at 12 months after graft implantation. Patency rates for above-knee femoropopliteal grafts were numerically superior to those of below-knee grafts in each treatment arm. These differences did not attain statistical significance, but the study was not powered to assess the results in the above-knee vs below-knee femoropopliteal subgroups. The data confirmed a reduction in bleeding at the anastomotic suture hole in the FUSION BIOLINE group, a finding with economic implications related to the use of local hemostatic agents and blood products as well as operative time. Although longer-term data will not be generated from the FINEST Trial, the primarily antithrombotic and more controversial antiproliferative effects of heparin would suggest that the most notable benefit in patency would be demonstrated early rather than late.
The 12-month primary patency rates observed in the FINEST Trial were similar to reported results of retrospective, single-arm, and single-center studies of heparincoated femoropopliteal grafts. The 1-year primary patency of heparin-coated femoropopliteal grafts in prior studies ranged from 71.6% to 92%. 19, 30 The FINEST study results are also aligned with data from prospective studies with protocol-specified duplex ultrasound imaging at followup visits. The 12-month primary patency rates were 80% in the above-knee and 75% in the below-knee subgroups of the Propaten (W. L. Gore and Associates, Flagstaff, Ariz) Italian Registry, a prospective single-arm study that mandated duplex ultrasound imaging and ABI in followup. 33 The Propaten European Product Evaluation (PEPE II) multicenter prospective European registry observed 12-month primary patency rates of 82.7% in above-knee and 74.2% in below-knee heparin-bonded femoropopliteal grafts. 34 Lastly, the multicenter randomized Scandinavian study documented a 12-month primary patency rate of 80.4% in the heparin-bonded femoropopliteal grafts, which was a significant improvement over the 69.6% rate observed in the standard ePTFE group of that study. 19 The Propaten U.S. IDE study design most closely resembled the FINEST Trial, although the two studies differed in the control devices and the inclusion in FINEST of below-knee femoropopliteal grafts. The Propaten IDE study was a randomized multicenter trial designed to demonstrate substantial equivalence between Propaten and the standard Gore-Tex Stretch graft in 200 patients requiring above-knee femoropopliteal bypass. Results of this study are summarized in the Propaten instructions for use, but were never published. 35, 36 The 12-month primary patency rate was reported as 67.2% and 71.2% in the Propaten group, which is nearly identical to the corresponding patency rate of 67.2% and 70.0% in the Gore-Tex Stretch control group in that study (percentages refer to the 2006 and 2012 instructions for use, respectively). The Propaten patency rates appear to be similar to the standard ePTFE rates observed in the FINEST trial and modestly inferior to the 12-month primary patency rate of 75.3% observed with the FUSION BIOLINE graft. The rate of graft infection appeared similar in the Propaten and FINEST studies, 2% vs 3%, respectively. However, comparisons between the two US IDE studies should be made with caution because the trial methodology and statistical analyses were different. Although the FINEST study is a prospective, multicenter, randomized trial, it has some limitations. First, the follow-up period was limited to 12 months, potentially missing a convergence of patency rates over longer-term follow-up. Second, the presence of a heparin coating is not the only difference between the test and control devices. The EXXCEL Soft control device was chosen as a standard-of-care comparator. The inner layer of the FUSION BIOLINE graft was identical in composition to the control device, but one cannot exclude the mechanical properties of the polyester external layer as the explanation for improved patency. Lastly, the choice of suture, intraoperative heparin and protamine regimen, and use of topical hemostatic agents was left to the surgeon's discretion, aspects of perioperative care that could affect outcome. 
